Roche diabetes drug hits targets

Roche diabetes drug taspoglutide has hit its targets, with the pharmaceutical company claiming that Phase III clinical trials have met their primary endpoints according to most recent studies.
The Swiss diabetes drug manufacturer Roche Holding AG reportedly said on Wednesday that a diabetes treatment currently undergoing Phase III clinical trials had been a success. Roche licensed the drug from French drugmaker Ipsen in 2006 after it showed a superior reduction of HbA1c levels.
How the diabetes drug comes to market depends on final reports of its efficiency, and approval by the drug regulators around the world. A number of pharmaceutical companies are thought to have diabetes drugs currently in the pipeline.